ArticleAnimal models and experimental medicine2025
Insight into pericytes in glioblastoma angiogenesis: In vivo tracking by two-photon microscopy and proteomic profiling.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging In Vivo Imaging Modalities for Improved Glioblastoma Surgery and Monitoring.Biomedicines · 2026Review
- Insight into pericytes in glioblastoma angiogenesis: In vivo tracking by two-photon microscopy and proteomic profiling.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a highly aggressive brain tumor characterized by aberrant angiogenesis and an immunosuppressive microenvironment. Pericytes are aberrantly recruited but their spatiotemporal roles and molecular changes remain unclear. This study investigated platelet-derived growth factor receptor beta-positive (Pdgfrb
methodsWe generated GL261-Luc and GL261-CFP glioblastoma cells via lentiviral transduction and established two transgenic models. (1) For pericyte labeling, Ai14 reporter mice was crossed with PDGFRβ-P2A-CreER
resultsCre-mediated ablation of Pdgfrb-expressing cells revealed stage-dependent effects on GBM growth: early ablation inhibited progression while late ablation promoted it. Pericytes undergo dual spatial reorganization in GBM: regional enrichment with pre-sprouting accumulation at the tumor-brain interface, and focal positioning with preferential localization at vascular branch points. Concurrently, GBM vasculature displayed simplified branching, dilation, and pericyte remodeling (shorter processes, higher density). Proteomics revealed 1426 altered proteins, with upregulated proliferation pathways (e.g., matrix metallopeptidase 14 [Mmp14], lysyl oxidase like 2 [Loxl2]) and downregulated homeostasis functions (e.g., transforming growth factor beta 1 [Tgfb1]), validated by scRNA-seq in human GBM.
conclusionsThis study demonstrates that during early GBM progression, pericytes actively drive tumor angiogenesis through molecular reprogramming toward proliferative and pro-angiogenic phenotypes, with the integrated imaging-proteomics framework revealing potential therapeutic targets for disrupting pericyte-mediated vascular remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.